Background: While most cancer cells preferentially express the M2 isoform of the glycolytic enzyme pyruvate kinase (PKM2), PKM2 is dispensable for tumor development in several mouse cancer models. PKM2 is expressed in human pancreatic cancer, and there have been conflicting reports on the association of PKM2 expression and pancreatic cancer patient survival, but whether PKM2 is required for pancreatic cancer progression is unknown. To investigate the role of PKM2 in pancreatic cancer, we used a conditional allele to delete PKM2 in a mouse model of pancreatic ductal adenocarcinoma (PDAC). Results: PDAC tumors were initiated in LSL-Kras
Introduction
Pyruvate kinase is an enzyme that catalyzes the final step of glycolysis to convert phosphoenolpyruvate and ADP to pyruvate and ATP. Pyruvate kinase has four isoforms encoded by two genes. The PKLR gene encodes PKL, which is expressed primarily in the liver, and PKR, which is expressed in erythrocytes [1] . The PKM gene encodes both the PKM1 and PKM2 isoforms, with isoform selected determined by alternate mRNA splicing to include either exon 9 or 10 [2, 3] . Both PKM isoforms catalyze the same reaction in glycolysis, but PKM1 has constitutively high catalytic activity, whereas the catalytic activity of PKM2 is allosterically regulated [2, 4] . As a glycolytic enzyme, PKM2 can exist in either a low activity state that promotes biosynthesis or in a high activity state that is similar to that of PKM1 and promotes oxidative glucose metabolism [2] . PKM2 is expressed in a variety of cancer types, and both metabolic and non-metabolic functions for PKM2 in cancer have been proposed [5] [6] [7] [8] [9] [10] . However, accumulating evidence suggests that PKM2 is not required for the growth or progression of most tumors, and non-metabolic roles for PKM2 remain controversial [11] [12] [13] [14] [15] [16] [17] [18] . For instance, deletion of PKM2 has been shown to promote tumor progression in breast cancer and medulloblastoma models [14, 15] and a recent study found that systemic PKM2 depletion (while maintaining PKM1 expression) promoted tumorigenesis [18] . However, other studies have found that PKM2 is dispensable for development of leukemia, liver cancer, colon cancer, lymphoma, lung cancer, and squamous cell carcinoma [16] [17] [18] . Thus, the role of PKM2 in cancer may depend on the genetic and/or environmental context.
Reports regarding the role of PKM2 in pancreatic cancer have also been conflicting. PKM2 has been reported to promote proliferation, migration, invasion, and angiogenesis and to decrease apoptosis in pancreatic cancer cell lines [19] [20] [21] . Other cell line studies have reported that PKM2 expression is important for gemcitabine resistance [22] [23] [24] [25] [26] . High PKM2 expression in human pancreatic tumors has been associated with larger tumor size, worse overall survival, and shorter recurrence-free survival of pancreatic cancer patients [20, 24, 27, 28] . However, one study reported that higher PKM2 expression was associated with longer overall survival of pancreatic cancer patients [29] , and other analyses found that expression of PKM2 had no effect on overall survival in pancreatic cancer [30, 31] .
Given the controversy surrounding the role of PKM2 in pancreatic tumors, we evaluated the importance of PKM2 in PDAC by crossing mice harboring a conditional Pkm2 allele [14] to the LSL-Kras G12D/+ ;Trp53 flox/ flox ;Pdx-1-Cre (KP −/− C) mouse PDAC model [32] . By comparing mice with and without PKM2 conditional alleles, we aimed to determine the requirement for PKM2 in pancreatic cancer.
Results
To examine PKM2 isoform expression in the pancreas and in pancreatic tumors, we performed immunohistochemistry on normal mouse pancreatic tissue and mouse pancreatic tumor tissue sections using PKM2 or PKM1 isoform-specific antibodies [14] . PKM1 and PKM2 staining was prominent in the islets of normal mouse pancreas, whereas the rest of the pancreas exhibited minimal PKM1 or PKM2 expression (Fig. 1a) , consistent with previously published reports [1] . Compared to the normal pancreas, end-stage PDAC tumors from LSL-Kras G12D/+ ; Trp53 (Fig. 1a) or LSL-Kras G12D/+ ;LSL-Trp53 R172H/+ ;Pdx-1-Cre (KPC) [33] (Additional file 1: Figure S1A ) mice showed increased staining for PKM2 and minimal PKM1 staining. This expression pattern was further verified by Western blot analysis of tissue lysates (Fig. 1b) . To examine PKM2 expression in human pancreatic tumors, we performed PKM2 immunohistochemistry on 68 pancreatic tumor tissue samples using a tissue array. All of the samples analyzed stained positive for PKM2 expression (Fig. 1c) .
To delete Pkm2 in PDAC tumors, mice harboring a conditional Pkm2 allele (Pkm2 flox/flox ) [14] were crossed to KP −/− C mice [32] . Overall survival was not significantly different between the KP −/− C;Pkm2 +/+ mice and the KP −/− C;Pkm2 flox/flox mice (Fig. 2a) , and there were no significant differences in weight of end-stage tumors in the KP −/− C;Pkm2 tumor lysates showed that these tumors almost exclusively expressed PKM2 (Fig. 3b) ; qPCR analysis of KP −/ − C;Pkm2 +/+ tumor RNA also showed PKM2 expression and very little PKM1 expression (Fig. 3c) . Western blotting of KP −/− C;Pkm2 flox/flox tumor lysates showed low PKM2 expression and high PKM1 expression (Fig. 3b) . Similarly, qPCR analysis of KP −/− C;Pkm2 flox/flox tumor RNA showed increased PKM1 expression and decreased PKM2 expression, although PKM1 mRNA expression was much lower than that observed in the brain, a tissue that normally expresses PKM1 [1] (Fig. 3c ). To investigate whether PKLR expression was induced by PKM2 loss, we also performed Western blot and qPCR analysis for PKLR. Neither KP . qPCR analysis was also performed for PKM2 skip, a PKM isoform that excludes exons 9 and 10, which has been reported to be expressed in PKM2 flox/flox mice in other models [14] . KP −/− C;Pkm2
tumors did not express PKM2 skip, while KP −/ − C;Pkm2 flox/flox tumors expressed PKM2 skip message at detectable levels (Additional file 1: Figure S2C ).
To compare cell proliferation in KP −/− C;Pkm2 +/+ and KP −/− C;Pkm2 flox/flox tumors, we performed immunohistochemical staining with antibodies against the proliferative markers Ki67 or PCNA (Fig. 4a-d) . There was no statistically significant difference in Ki67 or PCNA staining between KP −/− C;Pkm2 +/+ and KP −/− C;Pkm2 flox/flox tumors ( Fig. 4b, d ). To determine if the proliferating cells expressed pyruvate kinase, we stained serial sections for PCNA or PKM1 (Fig. 4c) . KP −/− C;Pkm2 
Discussion
These results argue that PKM2 expression has no significant effect on tumor initiation or progression in a mouse pancreatic cancer model driven by mutant Kras and ;Pdx-1-Cre (KP −/− C) mice were stained with hematoxylin and eosin (H&E) and isoform-specific antibodies against PKM2 or PKM1 as shown. Scale bars represent 50 μm for all images at × 20 magnification (top) and 20 μm for all images at × 40 magnification (bottom). b Western blot of normal mouse pancreas and mouse PDAC tumor lysates (from KP −/− C mice) performed using isoform-specific antibodies against PKM1 and PKM2 as well as an antibody against vinculin as a control. c Distribution of PKM2 staining intensities from a tissue microarray containing sections from 68 human pancreatic adenocarcinoma tumors deletion of both copies of Trp53. Although PKM2 is highly expressed in both mouse and human PDAC tumors, deletion of PKM2 had no effect on tumor size or survival of PDAC tumor-bearing mice. Our findings are consistent with meta-analyses of published datasets examining PKM2 expression and survival of human pancreatic cancer patients, which found that expression of PKM2 had no effect on overall survival [30, 31] . Our findings that PKM2 expression is not required for pancreatic tumor growth are consistent with findings from other cancer models showing that PKM2 is similarly not required for tumor development. This includes mouse models of colon cancer [12] , breast cancer [14] , medulloblastoma [15] , leukemia [16] , hepatocellular carcinoma [17, 18] , lymphoma [18] , lung cancer [18] , and squamous cell carcinoma [18] . While deletion of PKM2 accelerated breast cancer and medulloblastoma progression and promoted hepatocellular carcinoma [14, 15, 17] , loss of PKM2 slowed leukemia progression [16] and had no effect on progression of colon cancer [12] . A recent report using PKM1 and PKM2 knock-in mouse models showed that mice that exclusively expressed PKM1 had higher tumor burden than PKM2-expressing mice in a lung adenocarcinoma model [18] . Additionally, these whole-body PKM1-expressing mice had higher tumor incidence than PKM2-expressing mice in a carcinogen-induced mouse model [18] . We find here that deletion of PKM2 does not impair PDAC tumorigenesis or affect mouse survival or tumor size, suggesting that whether loss of PKM2 accelerates or slows cancer depends on the tissue and environmental context. PKM2 expression was relatively high in wild-type PDAC tumors, whereas PKM1 expression was low in these tumors. PKM2 deletion in tumors resulted in an isoform switch from PKM2 to PKM1 expression. This result is consistent with findings observed in colon cancer [12] , breast cancer [14] , and leukemia [16] and suggests that PKM2 is dispensable in a variety of tumor types. PKM1 expression has been associated with decreased proliferative capacity in some systems [5, 6, 14] although a recent study reported that PKM1 expression can also be associated with increased proliferation in tumors [18] . Although we observed higher PKM1 expression in PKM2 deleted tumors compared to wild-type Differences between our results and previously published reports may be attributed to the possibility that PKM2 was not efficiently deleted from all of the PDAC tumor cells, despite the fact that we observed a robust decrease in PKM2 expression in these tumors. Additionally, it is likely that tumor stromal cells, which make up a significant percentage of PDAC tumors [34] , retained PKM2 expression. Furthermore, it will be interesting to investigate PKM2 loss in other mouse models of pancreatic cancer driven by Kras with wildtype, heterozygous, or point mutant Trp53 [32, 33] . Different metabolic requirements may exist in these tumors that arise more gradually, such as a differential dependence on autophagy [35] . Nonetheless, the loss of PKM2 expression in most tumor cells in a mouse PDAC model driven by mutant Kras and early homozygous loss of Trp53 supports the notion that PKM2 is not generally required for PDAC initiation and progression. Although PKM2 is C Pkm2 flox/flox mice was performed using isoform-specific antibodies against PKM2 or PKM1 as well as an antibody against vinculin as a control. c PKM2 and PKM1 expression was assessed by qPCR in tumors arising in KP −/− C Pkm2 +/+ and KP −/− C Pkm2 flox/flox mice highly expressed in mouse and human PDAC, our findings support a model where PKM2 is dispensable for the growth of these cancers.
Conclusions
Our study found that PKM2 is not required for KP −/− C pancreatic tumor growth or progression. Although PKM2 was found to be highly expressed in mouse and human PDAC tumors, loss of PKM2 in KP −/− C mice did not significantly affect overall survival, tumor size, or proliferative index. Loss of PKM2 in PDAC tumors resulted in higher PKM1 expression, but did not change cell proliferation, further arguing that PKM2 is not required for pancreatic tumor growth.
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